Previous Close | 0.4390 |
Open | 0.4500 |
Bid | 0.4300 x 3000 |
Ask | 0.5100 x 900 |
Day's Range | 0.4300 - 0.4560 |
52 Week Range | 0.3200 - 0.7500 |
Volume | |
Avg. Volume | 176,186 |
Market Cap | 21.637M |
Beta (5Y Monthly) | -0.12 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4300 |
Earnings Date | Apr 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Erasmus Medical Center Erasmus Medical Center OCALA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the publication of new data analysis from a long-term Early Access Program (“EAP”) studying the company’s drug Ampligen® (rintatolimod) for the treatment of advanced pancreatic ductal adenocarcinoma (“PDAC”). The manuscript
OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, provided a corporate overview, a business outlook and discussed the AIM opportunity as part of the Virtual Investor Lunch Break series. The CEO Corner segment is now available here. About AIM ImmunoTech Inc. AI